Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/F2RL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/F2RL1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/F2RL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/F2RL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00622071 | Stomach | CSG | regulation of pattern recognition receptor signaling pathway | 13/1034 | 105/18723 | 5.15e-03 | 4.18e-02 | 13 |
GO:012003411 | Stomach | CSG | positive regulation of plasma membrane bounded cell projection assembly | 13/1034 | 105/18723 | 5.15e-03 | 4.18e-02 | 13 |
GO:00026901 | Stomach | CSG | positive regulation of leukocyte chemotaxis | 12/1034 | 94/18723 | 5.52e-03 | 4.42e-02 | 12 |
GO:004544621 | Stomach | CSG | endothelial cell differentiation | 14/1034 | 118/18723 | 5.54e-03 | 4.44e-02 | 14 |
GO:00025734 | Stomach | CSG | myeloid leukocyte differentiation | 21/1034 | 208/18723 | 5.63e-03 | 4.50e-02 | 21 |
GO:004440331 | Stomach | CAG | biological process involved in symbiotic interaction | 28/552 | 290/18723 | 4.03e-08 | 4.39e-06 | 28 |
GO:190290331 | Stomach | CAG | regulation of supramolecular fiber organization | 30/552 | 383/18723 | 1.27e-06 | 8.20e-05 | 30 |
GO:00019063 | Stomach | CAG | cell killing | 19/552 | 188/18723 | 3.13e-06 | 1.55e-04 | 19 |
GO:004206031 | Stomach | CAG | wound healing | 30/552 | 422/18723 | 8.89e-06 | 3.78e-04 | 30 |
GO:190495131 | Stomach | CAG | positive regulation of establishment of protein localization | 25/552 | 319/18723 | 9.63e-06 | 4.05e-04 | 25 |
GO:007259331 | Stomach | CAG | reactive oxygen species metabolic process | 20/552 | 239/18723 | 2.93e-05 | 1.02e-03 | 20 |
GO:19030343 | Stomach | CAG | regulation of response to wounding | 16/552 | 167/18723 | 3.60e-05 | 1.18e-03 | 16 |
GO:00610413 | Stomach | CAG | regulation of wound healing | 14/552 | 134/18723 | 4.24e-05 | 1.35e-03 | 14 |
GO:190290531 | Stomach | CAG | positive regulation of supramolecular fiber organization | 18/552 | 209/18723 | 4.99e-05 | 1.53e-03 | 18 |
GO:00713563 | Stomach | CAG | cellular response to tumor necrosis factor | 19/552 | 229/18723 | 5.18e-05 | 1.55e-03 | 19 |
GO:00305953 | Stomach | CAG | leukocyte chemotaxis | 19/552 | 230/18723 | 5.49e-05 | 1.60e-03 | 19 |
GO:005087831 | Stomach | CAG | regulation of body fluid levels | 26/552 | 379/18723 | 6.35e-05 | 1.82e-03 | 26 |
GO:00346123 | Stomach | CAG | response to tumor necrosis factor | 20/552 | 253/18723 | 6.54e-05 | 1.85e-03 | 20 |
GO:005122231 | Stomach | CAG | positive regulation of protein transport | 22/552 | 303/18723 | 1.02e-04 | 2.63e-03 | 22 |
GO:00603263 | Stomach | CAG | cell chemotaxis | 22/552 | 310/18723 | 1.41e-04 | 3.32e-03 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2RL1 | SNV | Missense_Mutation | rs185549069 | c.308N>A | p.Arg103Gln | p.R103Q | P55085 | protein_coding | deleterious(0.04) | benign(0.103) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.946A>T | p.Ser316Cys | p.S316C | P55085 | protein_coding | tolerated(0.05) | possibly_damaging(0.882) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | insertion | Nonsense_Mutation | novel | c.703_704insCACATAAGTTAGCATAACATGCTAA | p.Leu235SerfsTer6 | p.L235Sfs*6 | P55085 | protein_coding | | | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | insertion | Frame_Shift_Ins | novel | c.947_948insAAATATTGATCTCTACATCCCCCAACACTCCA | p.Ser316ArgfsTer24 | p.S316Rfs*24 | P55085 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1076T>C | p.Leu359Pro | p.L359P | P55085 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2RL1 | SNV | Missense_Mutation | novel | c.998N>G | p.Ser333Cys | p.S333C | P55085 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
F2RL1 | SNV | Missense_Mutation | novel | c.945N>C | p.Lys315Asn | p.K315N | P55085 | protein_coding | tolerated(0.26) | probably_damaging(0.913) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Asp340Asn | p.D340N | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1019N>G | p.Asp340Gly | p.D340G | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | | c.376N>G | p.Ile126Val | p.I126V | P55085 | protein_coding | tolerated(0.34) | benign(0.012) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ERYTHROMYCIN | ERYTHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | AC-55541 | CHEMBL493076 | 18720984 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100874 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ROXITHROMYCIN | ROXITHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 381744949 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103272 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103271 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100746 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103269 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103270 | | |